Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Improvement: type 7 spinocerebellar ataxia

Last update: 19/08/2024 Reading time: 1 min
FRAMES : un essai thérapeutique sur l'ataxie de Friedreich

The aim of Dr A. Sittler, from the Alexis Brice and Giovanni Stevanin team, is to develop a new therapeutic strategy for the spinocerebellar ataxia SCA7.

A. Sittler and her colleagues have previously shown, in a cell model of spinocerebellar ataxia SCA7, that interferon-beta induces the expression of promyelocytic leukemia protein (PML) and the formation of PML nuclear bodies that degrade mutant ataxin-7, suggesting that the cytokine, used to treat multiple sclerosis, might have therapeutic value in SCA7. We now show that interferon-beta also induces PML-dependent clearance of ataxin-7 in a preclinical model, SCA7266Q/5Q knock-in mice, and improves motor function. Immunohistological studies in brains from two SCA7 patients confirmed that these modifications are also caused by the disease in humans.

 

The treatment induced PML expression and the formation of PML nuclear bodies and decreased mutant ataxin-7 in neuronal intranuclear inclusions, the hallmark of the disease. No reactive gliosis or other signs of toxicity were observed in the brain or internal organs. The performance of the SCA7266Q/5Q knock-in mice was significantly improved on two behavioral tests sensitive to cerebellar function. In addition to motor dysfunction, SCA7266Q/5Q mice present abnormalities in the retina as in patients: ataxin-7-positive neuronal intranuclear inclusions which were reduced by interferon-beta treatment. Finally, since neuronal death does not occur in the cerebellum of SCA7266Q/5Q mice, we showed in primary cell cultures expressing mutant ataxin-7 that interferon-beta treatment improves Purkinje cell survival.

The interferon beta treated mouse cerebellum shows some modifications within Purkinje cells involved in the SCA7 pathology.

The interferon beta treated mouse cerebellum shows some modifications within Purkinje cells involved in the SCA7 pathology.

Left column: The interferon beta no treated mouse

Right column: the interferon beta treated mouse

- A and B: Visualization of the interferon beta. The Purkinje cells are deeper labeled (dark brown) in B, see the black arrows.

- C and D: Visualization of the PML protein. On the D picture, a lot of dark brown dots (PML nuclear bodies) are located inside the cells (black arrows). On C picture, the dark brown dots are rare and very small.

- E and F: Visualization of the mutant Ataxin 7 protein (green). E: three large inclusions of the pathogenic protein are present in a Purkinje cell. F: the inclusions are very smaller after the interferon beta treatment.

Sources

A.Chort et al. 2013, Interferon-beta induces clearance of mutant ataxin-7 and improves locomotion in SCA7 knock-in mice, Brain 10 : 1-14; doi : 10.1093/brain/awt061

Our news on the subject

Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them ...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain ...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol ...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and ...
06.28.2024 Research, science & health
Une tête de statue de l'île de Pâques sur laquelle sont posées des éléctrodes
A multimodal approach to better predict recovery in patients with disorders of consciousness
When a patient is admitted to intensive care due to a disorder of consciousness—such as a coma—establishing their neurological prognosis is a crucial yet challenging task. To reduce the uncertainty that precedes the medical decision, a group of ...
05.30.2024 Research, science & health
Population de bactéries commensales (en rouge) dans un intestin grêle de souris. Crédit : University of Chicago
The composition of the gut microbiota could influence decision-making
The way we make decisions in a social context can be explained by psychological, social, and political factors. But what if other forces were at work? Hilke Plassmann and her colleagues from the Paris Brain Institute and the University of Bonn show ...
05.16.2024 Research, science & health
See all our news